ArticleMetabolism open2026
Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults.
Article in Metabolism open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes?Clinical medicine (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Liver fibrosis is the key determinant of prognosis in metabolic dysfunction-associated steatotic liver disease (MASLD). While obesity is a major risk factor, whether regional adipose tissue distribution differentially relates to fibrosis independent of overall adiposity remains unclear. Methods: We analyzed data from 3668 U S. adults participating in NHANES 2017-2018 with available dual-energy X-ray absorptiometry and vibration-controlled transient elastography. Visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (aSAT), and thigh subcutaneous adipose tissue (tSAT) were expressed as percentages of total fat mass (VAT%, aSAT% and tSAT%). Clinically significant fibrosis was defined as liver stiffness measurement >8.0 kPa. Survey-weighted logistic regression models were used with sequential adjustment for demographic factors, lifestyle factors, and body mass index (BMI). Results: Clinically significant fibrosis was present in 9.7% of participants. Higher tSAT% was consistently associated with lower odds of fibrosis across all models. In the fully adjusted model, each 1% increase in tSAT% was associated with lower odds of fibrosis (odds ratio 0.91, 95% confidence interval 0.84-0.99). In contrast, VAT% was not independently associated with fibrosis. The association between aSAT% and fibrosis was not significant after multivariable adjustment. Conclusions: Regional fat distribution exhibits heterogeneous associations with liver fibrosis. Thigh subcutaneous fat shows an inverse association with fibrosis that persists after adjustment for overall adiposity (BMI), whereas abdominal fat depots do not. These findings highlight fat distribution as a clinically relevant dimension beyond total adiposity for refining fibrosis risk stratification in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.